Vancomycin-supplemented cancellous bone allografts in hip revision surgery

Area of Science:

• Orthopaedic Surgery
• Biomaterials Science
• Infectious Disease Control

Background:

• Hip revision surgery often requires bone allografts.
• Infection remains a significant complication in these procedures.
• Vancomycin supplementation is explored to enhance allograft safety and efficacy.

Purpose of the Study:

• To evaluate the effect of vancomycin on cancellous bone allograft incorporation in hip revision surgery.
• To assess the elution, bioactivity, and safety profile of vancomycin in patients.
• To determine the clinical efficacy of vancomycin-supplemented allografts in preventing infection and ensuring graft stability.

Main Methods:

• Animal study (18 pigs) using radiographs, histology, and immunohistochemistry to assess graft incorporation.
• Pharmacokinetic and safety analysis in 20 patients measuring vancomycin elution, bioactivity, and nephrotoxicity.
• Clinical follow-up of 30 patients for infection control and graft resorption over a minimum of 2 years.

Main Results:

• Vancomycin did not significantly impair bone graft incorporation in animal models.
• Achieved high local vancomycin concentrations (average 367.19 µg/mL) with no observed nephrotoxicity in patients.
• Demonstrated a low reinfection rate (3.3%) and no graft resorption in 30 patients at 2-year follow-up.

Conclusions:

• Vancomycin-supplemented cancellous bone allografts are safe and effective for hip revision surgery.
• This technique provides excellent infection control and maintains graft integrity.
• Supports the continued use of vancomycin-augmented allografts in reconstructive orthopaedics.